Not Too Many Surprises in Theravance (THRX) Breo Briefing Docs, Baird Said
Tweet Send to a Friend
Baird analyst Brian Skorney weighed in on Theravance Inc. (NASDAQ: THRX) after the FDA posted briefing documents ahead of Breo's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
